Cosentyx Insurance Denial Appeal Guide

Why Cosentyx Gets Denied

Cosentyx costs approximately $6,000/month. Insurers typically require failure of at least one TNF inhibitor before approving IL-17 inhibitors. Some plans also require failure of methotrexate or other conventional treatments first.

Common Denial Reasons

• Step therapy not met (TNF inhibitor trial required)
• Prior authorization missing
• Body surface area (BSA) threshold not met for psoriasis (typically >10%)
• PASI score documentation missing
• Preferred biologic available (Humira, Enbrel)

How to Build Your Appeal

1. Document disease severity — PASI scores, BSA measurements, photographs
2. List all failed treatments — topicals, phototherapy, methotrexate, biologics
3. Include quality of life impact — DLQI scores, work disability, psychological impact
4. Dermatologist letter — should reference AAD guidelines and explain why IL-17 is needed
5. Cite clinical superiority — Cosentyx has shown superior efficacy to TNF inhibitors in head-to-head trials for psoriasis

Documentation Checklist

• PASI and BSA scores at multiple timepoints
• Photographs of affected areas (with patient consent)
• DLQI quality of life questionnaire
• Complete treatment history with dates and outcomes
• Specialist letter of medical necessity